{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:24:40Z","timestamp":1787307880133,"version":"build-2736575974"},"reference-count":107,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FOCUS project: Training and Guidance for UMFST Researchers in Health","award":["100455\/29.08.2025"],"award-info":[{"award-number":["100455\/29.08.2025"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Heart failure management remains a critical clinical challenge. While modern neurohormonal therapies have significantly improved survival, standard clinical assessments often fail to capture the full complexity of underlying structural disease progression. To comprehensively synthesize the established literature regarding the biological and prognostic roles of NT-proBNP, soluble ST2 (sST2), and Galectin-3 (Gal-3) and, subsequently, to propose a hypothesis-generating multimarker framework for HF risk stratification. A narrative review of the literature (2006\u20132026) was conducted across PubMed, Scopus, and Google Scholar. The synthesis focused on the clinical utility, phenotypic specificities, and methodological limitations of evaluating NT-proBNP, sST2, and Gal-3 concentrations. Evidence from the literature confirms that while NT-proBNP remains the gold standard for acute hemodynamic assessment. sST2 and Gal-3 provide complementary insights into active biomechanical strain and interstitial fibrotic remodeling; however, prospective randomized clinical trials demonstrating that sST2- or Gal-3-guided management improves clinical outcomes remain lacking. Based on these established findings, we propose an investigational four-step multimarker framework spanning from acute diagnosis to dynamic outpatient monitoring. This framework hypothesizes that integrating these pathways can better identify high-risk phenotypes that remain undetected by natriuretic peptides alone. The synergistic application of NT-proBNP, sST2, and Gal-3 offers a deeper pathophysiological evaluation of HF. However, our proposed biomarker-guided framework represents a set of testable research hypotheses. It requires prospective randomized validation before integration into routine clinical protocols for therapeutic titration.<\/jats:p>","DOI":"10.3390\/ijms27167480","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:31:59Z","timestamp":1787304719000},"page":"7480","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Clinical Value of NT-proBNP, sST2, and Galectin-3 in the Management of Heart Failure: From Diagnosis to Dynamic Monitoring: A Narrative Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0346-3177","authenticated-orcid":false,"given":"Diana Andreea","family":"F\u0103rca\u0219","sequence":"first","affiliation":[{"name":"Doctoral School of Medicine and Pharmacy, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"},{"name":"Emergency Institute for Cardiovascular Diseases and Transplantation of T\u00e2rgu Mure\u0219, 540136 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7299-118X","authenticated-orcid":false,"given":"Monica","family":"Tarcea","sequence":"additional","affiliation":[{"name":"Department of Community Nutrition and Food Safety, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7623-4343","authenticated-orcid":false,"given":"Maria Cristina","family":"T\u0103tar","sequence":"additional","affiliation":[{"name":"Department of Clinical and Surgical Disciplines, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mure\u0219, 540142 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda","family":"Cerghizan","sequence":"additional","affiliation":[{"name":"Department of Clinical and Surgical Disciplines, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mure\u0219, 540142 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u0103lin","family":"Cr\u0103ciun","sequence":"additional","affiliation":[{"name":"Department of Surgery III, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3167-5497","authenticated-orcid":false,"given":"Hajnal","family":"Finta","sequence":"additional","affiliation":[{"name":"Department of Public Health and Management, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0356-822X","authenticated-orcid":false,"given":"Florina","family":"Gliga","sequence":"additional","affiliation":[{"name":"Department of Physiopathology, Faculty of Medicine, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3235-524X","authenticated-orcid":false,"given":"Claudia","family":"B\u0103nescu","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, George Emil Palade University of Medicine, Pharmacy, Science, and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"100484","DOI":"10.1016\/j.cophys.2022.100484","article-title":"The heart under pressure: Immune cells in fibrotic remodeling","volume":"25","author":"Theall","year":"2022","journal-title":"Curr. Opin. Physiol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Perez, P.C., Gonz\u00e1lez-Juanatey, J.R., Nuche, J., Matute-Blanco, L., Serrano, I., Selles, M.M., Garc\u00eda, R.V., Dolz, L.M., G\u00f3mez-Bueno, M., and Figal, D.P. (2022). Renal function impact in the prognostic value of galectin-3 in acute heart failure. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.861651"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1210\/jc.2009-1619","article-title":"Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes","volume":"95","author":"Weigert","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e06","DOI":"10.15420\/cfr.2023.24","article-title":"Evaluating Biomarkers as Tools for Early Detection and Prognosis of Heart Failure: A Comprehensive Review","volume":"10","author":"Alzaabi","year":"2024","journal-title":"Card. Fail. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.36628\/ijhf.2023.0009","article-title":"Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Definition and Diagnosis","volume":"5","author":"Cho","year":"2023","journal-title":"Int. J. Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"17022","DOI":"10.1038\/s41598-019-53540-4","article-title":"Prevalence and progression of rheumatic heart disease: A global systematic review and meta-analysis of population-based echocardiographic studies","volume":"9","author":"Noubiap","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_8","unstructured":"Shams, P., Malik, A., and Chhabra, L. (2025). Heart Failure (Congestive Heart Failure). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2013.05.072","article-title":"Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme","volume":"62","author":"Wong","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"808","DOI":"10.4070\/kcj.2019.0199","article-title":"Tachycardia induced Cardiomyopathy","volume":"49","author":"Kim","year":"2019","journal-title":"Korean Circ. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF Stats 2024: Heart Failure Epidemiology and Outcomes Statistics: An Updated 2024 Report from the Heart Failure Society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J. Card. Fail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1002\/ejhf.70054","article-title":"What\u2019s new in heart failure? September 2025","volume":"27","author":"Hoevelmann","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_13","unstructured":"Ministerul S\u0103n\u0103t\u0103\u021bii (2021). Strategia Na\u021bional\u0103 de S\u0103n\u0103tate 2021\u20132027, Guvernul Rom\u00e2niei."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"100688","DOI":"10.1016\/j.jacadv.2023.100688","article-title":"BNP and NT-proBNP Thresholds for the Assessment of Prognosis in Patients Without Heart Failure","volume":"2","author":"Jehn","year":"2023","journal-title":"JACC Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/bs.acc.2023.11.005","article-title":"Natriuretic peptide testing strategies in heart failure: A 2023 update","volume":"118","author":"Chaikijurajai","year":"2024","journal-title":"Adv. Clin. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mouzarou, A., Hadjigeorgiou, N., Melanarkiti, D., and Plakomyti, T.E. (2025). The Role of NT-proBNP Levels in the Diagnosis of Hypertensive Heart Disease. Diagnostics, 15.","DOI":"10.3390\/diagnostics15010113"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ajh\/hpad065","article-title":"Prevalence of Elevated NT-proBNP and its Prognostic Value by Blood Pressure Treatment and Control","volume":"36","author":"Daya","year":"2023","journal-title":"Am. J. Hypertens."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107863","DOI":"10.1016\/j.pharmthera.2021.107863","article-title":"The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications","volume":"227","author":"Kuwahara","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Gastouniotis, I., Fragoulis, C., Antonopoulos, A., Kouroutzoglou, A., Noutsou, M., Thanopoulou, A., Chrysohoou, C., and Tsioufis, K.P. (2024). The Implication of NT-proBNP in the Assessment of the Clinical Phenotype of Patients with Type 2 Diabetes Mellitus, Without Established Cardiovascular Disease. Biomedicines, 12.","DOI":"10.3390\/biomedicines12122718"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e006541","DOI":"10.1161\/CIRCHEARTFAILURE.119.006541","article-title":"Comparison of BNP and NT-proBNP in patients with heart failure and reduced ejection fraction","volume":"13","author":"Jhund","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e010259","DOI":"10.1161\/CIRCHEARTFAILURE.122.010259","article-title":"Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial","volume":"16","author":"Jering","year":"2023","journal-title":"Circ. Heart Fail."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1016\/j.jacc.2016.10.001","article-title":"NT-proBNP: The Gold Standard Biomarker in Heart Failure","volume":"68","author":"McKie","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"l223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000\u20132017: Population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.jacc.2018.01.021","article-title":"N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study","volume":"71","author":"Januzzi","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jacc.2011.03.042","article-title":"Influence of sex and hormone status on circulating natriuretic peptides","volume":"58","author":"Lam","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Heinrich, M.A., Stark, K.J., Zimmermann, M.E., Herold, J.M., Brandl, C., Schober, A.D., Burkhardt, R., Maier, L.S., Luchner, A., and Heid, I.M. (Clin. Res. Cardiol., 2025). NT-proBNP in the very old population: Reference values and heart failure specificity from the AugUR-study, Clin. Res. Cardiol., ahead of print.","DOI":"10.1007\/s00392-025-02785-3"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Netala, V.R., Hou, T., Wang, Y., Zhang, Z., and Teertam, S.K. (2025). Cardiovascular Biomarkers: Tools for Precision Diagnosis and Prognosis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26073218"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e129979","DOI":"10.1172\/jci.insight.129979","article-title":"Racial differences in the association of NT-proBNP with risk of incident heart failure in REGARDS","volume":"5","author":"Patel","year":"2019","journal-title":"JCI Insight"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.15420\/cfr.2018.26.1","article-title":"Natriuretic Peptides in Chronic Heart Failure","volume":"5","year":"2019","journal-title":"Card. Fail. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/clc.24074","article-title":"N-terminal pro-B-type natriuretic peptide for prediction of ventricular arrhythmias: Data from the SMASH study","volume":"46","author":"Sourour","year":"2023","journal-title":"Clin. Cardiol."},{"key":"ref_31","first-page":"e004436","article-title":"Circulating ST2 levels and clinical outcomes in the PARADIGM-HF trial","volume":"11","author":"Prescott","year":"2018","journal-title":"Circ. Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.3346\/jkms.2019.34.e133","article-title":"Prognostic Effect of Guideline-Directed Therapy Is More Noticeable Early in the Course of Heart Failure","volume":"34","author":"Ahn","year":"2019","journal-title":"J. Korean Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Chevalier, C., Wendner, M., Suling, A., Cavus, E., Muellerleile, K., Lund, G., Kirchhof, P., and Patten, M. (2022). Association of NT-proBNP and hs-cTnT with Imaging Markers of Diastolic Dysfunction and Focal Myocardial Fibrosis in Hypertrophic Cardiomyopathy. Life, 12.","DOI":"10.3390\/life12081241"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yang, Y., Zmuda, J.M., Wojczynski, M.K., Thyagarajan, B., Christensen, K., Cvejkus, R.K., and Kuipers, A.L. (2021). Genetic association analysis of the cardiovascular biomarker: N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP). PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0248726"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15560","DOI":"10.1038\/s41598-022-19821-1","article-title":"Impact of socioeconomic and cardiovascular risk factors on the effect of genetic variants associated with NT-proBNP","volume":"12","author":"Matusch","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_36","first-page":"w02008","article-title":"Soluble ST2\u2014A New Biomarker in Heart Failure","volume":"22","author":"Patric","year":"2019","journal-title":"Cardiovasc. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1093\/eurheartj\/ehad335","article-title":"NT-proBNP and high intensity care for acute heart failure: The STRONG-HF trial","volume":"44","author":"Adamo","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-Vilella, R., G\u00f3mez-Otero, I., Donoso Trenado, V., Garc\u00eda-Vega, D., Otero-Garc\u00eda, \u00d3., Dolz, L.M., Gonz\u00e1lez-Juanatey, J.R., and Bonet, L.A. (2025). NT-proBNP in Acute De Novo Heart Failure: A Key Biomarker for Predicting Myocardial Recovery\u2014COMFE Registry. Life, 15.","DOI":"10.3390\/life15040526"},{"key":"ref_39","first-page":"145","article-title":"Soluble ST2 Testing: A Promising Biomarker in the Management of Heart Failure","volume":"106","author":"Villacorta","year":"2016","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/j.1460-2075.1994.tb06367.x","article-title":"Alternative promoter usage of the Fos-responsive gene Fit-1 generates mRNA isoforms coding for either secreted or membrane-bound proteins related to the IL-1 receptor","volume":"13","author":"Bergers","year":"1994","journal-title":"EMBO J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and Prognostic Significance of sST2 in Heart Failure: JACC Review Topic of the Week","volume":"74","author":"Aimo","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","article-title":"Identification of serum soluble ST2 receptor as a novel heart failure biomarker","volume":"107","author":"Weinberg","year":"2003","journal-title":"Circulation"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1002\/ehf2.14860","article-title":"Association of point-of-care testing for sST2 with clinical outcomes in patients hospitalized with heart failure","volume":"11","author":"Chen","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"86","DOI":"10.31083\/j.rcm2403086","article-title":"Sex-Specific Thresholds for Cardiac Biomarkers-We Need to Move Forward","volume":"24","author":"Lobo","year":"2023","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/rheumatology\/kep402","article-title":"Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus","volume":"49","author":"Mok","year":"2010","journal-title":"Rheumatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure","volume":"70","author":"Yancy","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jchf.2013.05.005","article-title":"PRAISE (Prospective Randomized Amlodipine Survival Evaluation) and Criticism","volume":"1","author":"Pfeffer","year":"2013","journal-title":"JACC Heart Fail."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Davini, F., Fogolari, M., D\u2019avanzo, G., Ristori, M.V., Nucciarelli, S., Bani, L., Cristiano, A., De Cesaris, M., Spoto, S., and Angeletti, S. (2025). Soluble Suppression of Tumorigenicity 2 (sST2) as a Diagnostic and Prognostic Marker in Acute Heart Failure and Sepsis: A Comparative Analysis. Diagnostics, 15.","DOI":"10.3390\/diagnostics15081010"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Aletras, G., Bachlitzanaki, M., Stratinaki, M., Lamprogiannakis, E., Petrakis, I., Foukarakis, E., Pantazis, Y., Hamilos, M., and Stylianou, K. (2025). Integrating Novel Biomarkers into Clinical Practice: A Practical Framework for Diagnosis and Management of Cardiorenal Syndrome. Life, 15.","DOI":"10.3390\/life15101540"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.2147\/IJGM.S435552","article-title":"sST2 and Big ET-1 as Alternatives of Multi-Biomarkers Strategies for Prognosis Evaluation in Patients Hospitalized with Heart Failure","volume":"16","author":"Chen","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1002\/ehf2.13883","article-title":"Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure","volume":"9","author":"Vergaro","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1016\/j.bbadis.2012.12.014","article-title":"Biomarkers and diagnostics in heart failure","volume":"1832","author":"Gaggin","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ejhf.749","article-title":"A multimarker multi-time point-based risk stratification strategy in acute heart failure: Results from the RELAX-AHF trial","volume":"19","author":"Demissei","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1093\/eurheartj\/ehz240","article-title":"Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial","volume":"40","author":"Morrow","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G.P., Bellotti, C., Salehi, L.B., and Ricci, A. (2018). Galectin-3: One Molecule for an Alphabet of Diseases, from A to Z. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020379"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Liu, T., and Yang, F. (2025). Galectin-3 in acute myocardial infarction: From molecular mechanisms to clinical translation. Front. Mol. Biosci., 12.","DOI":"10.3389\/fmolb.2025.1730173"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lorenzo-Almor\u00f3s, A., Pello, A., Ace\u00f1a, \u00c1., Mart\u00ednez-Milla, J., Gonz\u00e1lez-Lorenzo, \u00d3., Tar\u00edn, N., Crist\u00f3bal, C., Blanco-Colio, L.M., Mart\u00edn-Ventura, J.L., and Huelmos, A. (2020). Galectin-3 Is Associated with Cardiovascular Events in Post-Acute Coronary Syndrome Patients with Type-2 Diabetes. J. Clin. Med., 9.","DOI":"10.3390\/jcm9041105"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Screever, E.M., Gorter, T.M., Willems, T.P., Aboumsallem, J.P., Suthahar, N., Mahmoud, B., van Veldhuisen, D.J., de Boer, R.A., and Meijers, W.C. (2023). Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance Imaging Is Related to Galectin-3 and Predicts Outcome in Heart Failure. Biomolecules, 13.","DOI":"10.3390\/biom13030410"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"E327","DOI":"10.1532\/hsf.3547","article-title":"Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis","volume":"24","author":"Wu","year":"2021","journal-title":"Heart Surg. Forum"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s10741-019-09858-2","article-title":"Circulating galectin-3 on admission and prognosis in acute heart failure patients: A meta-analysis","volume":"25","author":"Chen","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"200","DOI":"10.3909\/ricm0624","article-title":"Galectin-3: A Novel Blood Test for the Evaluation and Management of Patients With Heart Failure","volume":"12","author":"McCullough","year":"2011","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Cheng, W., Fuernau, G., Desch, S., Freund, A., Feistritzer, H.-J., P\u00f6ss, J., Besler, C., Lurz, P., B\u00fcttner, P., and Thiele, H. (2022). Circulating Galectin-3 in Patients with Cardiogenic Shock Complicating Acute Myocardial Infarction Treated with Mild Hypothermia: A Biomarker Sub-Study of the SHOCK-COOL Trial. J. Clin. Med., 11.","DOI":"10.3390\/jcm11237168"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ahj.2014.02.011","article-title":"Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials","volume":"167","author":"Meijers","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_65","first-page":"599","article-title":"Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)","volume":"41","author":"Dong","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurjhf\/hfp097","article-title":"Galectin-3: A novel mediator of heart failure development and progression","volume":"11","author":"Voors","year":"2009","journal-title":"Eur. J. Heart Fail."},{"key":"ref_67","first-page":"129","article-title":"Galectin-3: A novel biomarker for the prognosis of heart failure","volume":"90","author":"Amin","year":"2017","journal-title":"Clujul Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zaborska, B., Sikora-Fr\u0105c, M., Smar\u017c, K., Pilichowska-Paszkiet, E., Budaj, A., Sitkiewicz, D., and Sygitowicz, G. (2023). The Role of Galectin-3 in Heart Failure\u2014The Diagnostic, Prognostic and Therapeutic Potential\u2014Where Do We Stand?. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713111"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lupu, A., Negreanu-Pirjol, T., Olariu, L., Negreanu-Pirjol, B.-S., Jurja, S., Lepadatu, A.C., Basa, M., and Rosoiu, N. (2026). Galectin-3\u2014A Multifunctional Molecule and a Key Player in Health and Disease. Molecules, 31.","DOI":"10.3390\/molecules31101694"},{"key":"ref_70","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jash.2017.03.008","article-title":"Galectin-3 mediates the pulmonary arterial hypertension-induced right ventricular remodeling through interacting with NADPH oxidase 4","volume":"11","author":"He","year":"2017","journal-title":"J. Am. Soc. Hypertens."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1038\/s41440-019-0291-x","article-title":"Alteration of the IL-33-sST2 pathway in hypertensive patients and a mouse model","volume":"42","author":"Yin","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.jacc.2011.03.072","article-title":"Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction","volume":"58","author":"Januzzi","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"120249","DOI":"10.1016\/j.cca.2025.120249","article-title":"A novel NT-proBNP assay for heart failure diagnosis: A prospective, multicenter clinical trial","volume":"572","author":"Guidi","year":"2025","journal-title":"Clin. Chim. Acta"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1016\/j.jacc.2008.07.042","article-title":"Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure","volume":"52","author":"Rehman","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hfc.2017.08.009","article-title":"Galectin-3 in Heart Failure: An Update of the Last 3 Years","volume":"14","author":"Gehlken","year":"2018","journal-title":"Heart Fail. Clin."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.12659\/MSM.908840","article-title":"Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction","volume":"24","author":"Cui","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.cca.2016.10.034","article-title":"Diagnostic and prognostic accuracy of galectin-3 and soluble ST2 for acute heart failure","volume":"463","author":"Mueller","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e002551","DOI":"10.1161\/CIRCHEARTFAILURE.115.002551","article-title":"Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI with ARB on Management of Heart Failure With Preserved Ejection Fraction Study","volume":"9","author":"Zile","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Basha, M., Stavropoulou, E., Nikolaidou, A., Dividis, G., Peteinidou, E., Tsioufis, P., Kamperidis, N., Dimitriadis, K., Karamitsos, T., and Giannakoulas, G. (2025). Diagnosing Heart Failure with Preserved Ejection Fraction in Obese Patients. J. Clin. Med., 14.","DOI":"10.3390\/jcm14061980"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.15420\/cfr.2024.26","article-title":"Obesity Phenotypes Causally Affect Cardiac MRI Structure and Induced Non-ischaemic Cardiomyopathy","volume":"11","author":"Peng","year":"2025","journal-title":"Card. Fail. Rev."},{"key":"ref_85","first-page":"1171","article-title":"Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure","volume":"63","author":"Januzzi","year":"2010","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/ehf2.14813","article-title":"Galectin-3 levels and long-term all-cause mortality and hospitalization in heart failure patients: A meta-analysis","volume":"11","author":"Cheng","year":"2024","journal-title":"ESC Heart Fail."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/CM9.0000000000000149","article-title":"Development of heart failure risk prediction models based on a multi-marker approach using random forest algorithms","volume":"132","author":"Yuan","year":"2019","journal-title":"Chin. Med. J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e01","DOI":"10.15420\/cfr.2024.32","article-title":"Biomarkers for Congestion in Heart Failure: State-of-the-art and Future Directions","volume":"11","author":"Parlati","year":"2025","journal-title":"Card. Fail. Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"91","DOI":"10.36628\/ijhf.2019.0014","article-title":"Management of Acute Heart Failure during an Early Phase","volume":"2","author":"Takagi","year":"2020","journal-title":"Int. J. Heart Fail."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"H1256","DOI":"10.1152\/ajpheart.00150.2018","article-title":"Galectin-3 in the pathogenesis of heart failure: A causative mediator or simply a biomarker?","volume":"314","author":"Kirk","year":"2018","journal-title":"Am. J. Physiol. Circ. Physiol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Tran, S.K., Ngo, T.H., Lai, T.T., Truong, G.K., Tran, K.D.D., Vo, P.M., Nguyen, P.T., Nguyen, P.H., Nguyen, T.T., and Nguyen, O.T.K. (2023). Effectiveness of Spironolactone in Terms of Galectin-3 Levels in Patients with Heart Failure with a Reduced Ejection Fraction in the Vietnamese Population. Healthcare, 11.","DOI":"10.3390\/healthcare11020253"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12265-013-9459-y","article-title":"ST2 as a cardiovascular risk biomarker: From the bench to the bedside","volume":"6","author":"Januzzi","year":"2013","journal-title":"J. Cardiovasc. Transl. Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wang, Z., Pan, X., Xu, H., Wu, Y., Jia, X., Fang, Y., Lu, Y., Xu, Y., Zhang, J., and Su, Y. (2022). Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.812654"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.repc.2014.10.005","article-title":"Galectin-3, a prognostic marker\u2014And a therapeutic target?","volume":"34","author":"Pereira","year":"2015","journal-title":"Rev. Port. Cardiol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cca.2015.03.033","article-title":"Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases","volume":"445","author":"Mueller","year":"2015","journal-title":"Clin. Chim. Acta"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jchf.2013.10.005","article-title":"Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure","volume":"2","author":"Gaggin","year":"2014","journal-title":"JACC Heart Fail."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/07853890.2010.538080","article-title":"Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction","volume":"43","author":"Lok","year":"2011","journal-title":"Ann. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00392-015-0811-x","article-title":"Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction","volume":"104","author":"Laszczynska","year":"2015","journal-title":"Clin. Res. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Buliga-Finis, O.N., Ouatu, A., Tanase, D.M., Badescu, M.C., Dima, N., Gosav, E.M., Popescu, D., and Rezus, C. (2025). The Role of Galectin-3 as a Biomarker in the Cardio\u2013Renal\u2013Metabolic Pathology Axis. J. Clin. Med., 14.","DOI":"10.3390\/jcm14176071"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.amjcard.2010.09.011","article-title":"Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction","volume":"107","author":"Mueller","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Sciatti, E., Merlo, A., Scangiuzzi, C., Limonta, R., Gori, M., D\u2019elia, E., Aimo, A., Vergaro, G., Emdin, M., and Senni, M. (2023). Prognostic Value of sST2 in Heart Failure. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123970"},{"key":"ref_102","first-page":"e86959","article-title":"Galectin-3 and Risk Stratification in Chronic Heart Failure: A Systematic Review of Mortality Outcomes","volume":"17","author":"Sulaiman","year":"2025","journal-title":"Cureus"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): A multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s43556-026-00438-z","article-title":"Machine learning integrated clinical-proteomics data identifies a 6-protein panel signature for atherosclerotic severity and enhanced patient stratification","volume":"7","author":"Olsen","year":"2026","journal-title":"Mol. Biomed."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3048941","DOI":"10.1155\/2018\/3048941","article-title":"The Utility of Point of Care Test for Soluble ST2 in Predicting Adverse Cardiac Events during Acute Care of ST-Segment Elevation Myocardial Infarction","volume":"2018","author":"Hartopo","year":"2018","journal-title":"Cardiol. Res. Pract."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Yan, C.L., and Grazette, L. (2023). A review of biomarker and imaging monitoring to predict heart failure recovery. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1150336"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijcard.2022.09.074","article-title":"Performance of a multi-biomarker panel for prediction of cardiovascular event in patients with chronic kidney disease","volume":"371","author":"Mohebi","year":"2023","journal-title":"Int. J. Cardiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7480\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T09:34:51Z","timestamp":1787304891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/16\/7480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":107,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27167480"],"URL":"https:\/\/doi.org\/10.3390\/ijms27167480","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}